Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
China Traditional Chinese Medicine Holdings Co has the Financial Strength Rank of 7.
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is rated on a scale of 1 to 10 and is based on these factors:
1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
2. Debt to revenue ratio. The lower, the better.
3. Altman Z-Score.
4. Other debt related ratios.
A higher score indicates a stronger financial position, with companies rated 7 or above considered financially stable and unlikely to face distress. Conversely, a score of 3 or below suggests potential financial difficulties, indicating a higher risk of distress.
China Traditional Chinese Medicine Holdings Co's Interest Coverage for the quarter that ended in Dec. 2025 was 5.66.
China Traditional Chinese Medicine Holdings Co's debt to revenue ratio for the quarter that ended in Dec. 2025 was 0.17.
As of today, China Traditional Chinese Medicine Holdings Co's Altman Z-Score is 1.54.
China Traditional Chinese Medicine Holdings Co (STU:WSG) Financial Strength Explanation
The rank is rated on a scale of 1 to 10. A higher score indicates a stronger financial position, with companies rated 7 or above considered financially stable and unlikely to face distress. Conversely, a score of 3 or below suggests potential financial difficulties, indicating a higher risk of distress.
China Traditional Chinese Medicine Holdings Co has the Financial Strength Rank of 7.
China Traditional Chinese Medicine Holdings Co Financial Strength Related Terms
STU:WSG vs ZTS: Financial Strength Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, China Traditional Chinese Medicine Holdings Co's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
China Traditional Chinese Medicine Holdings Co Financial Strength vs Drug Manufacturers Industry
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
The zones of discrimination were as such:
When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.
China Traditional Chinese Medicine Holdings Co has a Z-score of 1.54, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.
Warning Sign:
Altman Z-score of 1.54 is in distress zone. This implies bankruptcy possibility in the next two years.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
China Traditional Chinese Medicine Holdings Co (STU:WSG) has a Financial Strength of 7 as of Dec. 2025. The financial strength rank measures the strength of a company's balance sheet based on revenue and debt. View historical data on China Traditional Chinese Medicine Holdings Co and its competitors. This is near median its historical median of 7.00. Over the past decade, China Traditional Chinese Medicine Holdings Co's Financial Strength has ranged from 5.00 to 7.00.
Is China Traditional Chinese Medicine Holdings Co's Financial Strength too high?
China Traditional Chinese Medicine Holdings Co's current Financial Strength of 7 is near median its 10-year median of 7.00. Over the past 10 years, this metric has ranged from a low of 5.00 to a high of 7.00. Overall, China Traditional Chinese Medicine Holdings Co has a GF Score™ of 71/100, reflecting its overall financial health beyond just this single metric.
How does China Traditional Chinese Medicine Holdings Co's Financial Strength compare to ZTS?
China Traditional Chinese Medicine Holdings Co's Financial Strength of 7 can be compared against companies in the Drug Manufacturers industry. Historically, China Traditional Chinese Medicine Holdings Co's own Financial Strength has ranged from 5.00 to 7.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Financial Strength for a Drug Manufacturers company?
A good Financial Strength depends on the Drug Manufacturers industry context. However, Financial Strength should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Financial Strength mean?
A high Financial Strength can signal that a stock is expensive relative to its fundamentals. The financial strength rank measures the strength of a company's balance sheet based on revenue and debt. View historical data on China Traditional Chinese Medicine Holdings Co and its competitors. China Traditional Chinese Medicine Holdings Co's current Financial Strength is 7, which is near median its own 10-year median of 7.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China Traditional Chinese Medicine Holdings Co stock overvalued right now?
China Traditional Chinese Medicine Holdings Co (STU:WSG) has a current Financial Strength of 7. The stock's GF Value™ is €0.42, compared to a current price of €0.22 — trading 47.6% below its estimated fair value. The current Financial Strength is 7, which is near median its 10-year median of 7.00. China Traditional Chinese Medicine Holdings Co's overall GF Score™ is 71/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Financial Strength calculated?
Financial Strength is calculated from a company's financial statements. For China Traditional Chinese Medicine Holdings Co (STU:WSG), the current Financial Strength is 7 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is China Traditional Chinese Medicine Holdings Co (STU:WSG) Overvalued in 2026?
Based on GuruFocus' analysis, China Traditional Chinese Medicine Holdings Co stock appears to be undervalued.
The current stock price of €0.22 is trading 47.6% below its estimated GF Value™ of €0.42.
Key valuation signals for STU:WSG:
Financial Strength: 7 (near median its 10-year median of 7.00)
GF Value™: €0.42 vs. price of €0.22 (47.6% below fair value)
No single metric tells the full story. See the STU:WSG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
China Traditional Chinese Medicine Holdings Co Ltd is engaged in the Chinese healthcare sector. The company functions through four segments: Yi Fang, Tian Jiang, Tong Ji Tang, and Medi-World. It generates maximum revenue from the Yifang segment which mainly engages in the manufacture and sales of concentrated TCM granules (CTCMG), TCM healthcare products, and TCM decoction pieces under the Yi Fang brand. The majority of the revenue of the Yi Fang segment is derived from the sales of CTCMG. Geographically, it derives a majority of its revenue from Mainland China, and also has its presence in Hong Kong and Other countries.
71GF Score
Get the complete analysis for STU:WSG
Financial Strength is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:WSG has been successfully added to your 
